<DOC>
	<DOCNO>NCT00006480</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Inserting genetic material make laboratory person 's blood cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness biological therapy gene therapy treat child recurrent refractory neuroblastoma .</brief_summary>
	<brief_title>Biological Therapy Gene Therapy Treating Children With Recurrent Refractory Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity cellular immunotherapy use ex vivo expand autologous CD8+ cytotoxic T-lymphocyte clone genetically modify express CE7R scFvFc : zeta chimeric immunoreceptor HyTK selection/suicide gene child recurrent refractory disseminate neuroblastoma . II . Determine antitumor activity regimen patient . III . Determine duration vivo persistence adoptively transfer clone effect interleukin-2 maintaining vivo persistence clone . IV . Screen development host anti-scFvFc : zeta HyTK immune response patient treat regimen . V. Determine efficacy ganciclovir ablate transfer clone vivo toxicity occur patient . OUTLINE : This multicenter study . Patients undergo autologous peripheral blood stem cell harvest . CD8+ cytotoxic T-lymphocyte ( CTL ) clone isolate , genetically modify express CE7R scFvFc : zeta chimeric immunoreceptor HyTK selection/suicide gene , expand ex vivo . While modified CTL clone generate , patient receive individualized salvage chemotherapy regimen may consist one following : cyclophosphamide topotecan ; ifosfamide , carboplatin , etoposide ; another chemotherapy regimen choose patient 's primary oncologist . The first cohort 5 patient receive escalate dos modify CTL clone IV 30 minute day 0 , 14 , 28 absence disease progression unacceptable toxicity . Each patient begin series 3 infusion soon adequate number modify CTL clone ready acute side effect chemotherapy resolve . In absence unacceptable toxicity first cohort , second cohort 5 patient receive treatment cohort 1 plus interleukin-2 subcutaneously every 12 hour day 15-24 29-38 . Patients unacceptable toxicity receive ganciclovir IV every 12 hour 14 day ( longer symptomatic resolution achieve interval ) . Patients follow day 100 periodically thereafter . PROJECTED ACCRUAL : A total 10 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically and/or radiographically proven disseminate neuroblastoma Recurrent refractory firstline therapy define less complete response standard induction chemotherapy combine surgical resection Histologic verification neuroblastoma require original diagnosis No radiographically detectable CNS involvement No clinically evident progressive encephalopathy PATIENT CHARACTERISTICS : Age : 1 17 ( child ) Performance status : Not specify Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Not specify Renal : No dialysis dependency Cardiovascular : No uncontrolled cardiac arrhythmia No hypertension require pressor support Pulmonary : No requirement supplemental oxygen unless expect resolve within 2 week Neurologic : See Disease Characteristics No refractory seizure disorder Other : No detectable human antimouse antibody reactivity receive prior murine antibody preparations No history ganciclovir allergy intolerance HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent antibody therapy study No concurrent immunotherapy ( e.g. , interferon , vaccine , cellular product ) Chemotherapy : At least 3 week since prior standard experimental chemotherapy recover Endocrine therapy : No concurrent systemic corticosteroid unless specifically amelioration toxicity induce transfer Tcell therapy Radiotherapy : Not specify Surgery : Not specify Other : At least 3 week since prior immunosuppressive therapy recover No concurrent pentoxifylline No concurrent investigational agent No concurrent ganciclovir , ganciclovir derivative , acyclovir nonlifethreatening herpes virus infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>